Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Craig Gedye

Showing results (61-70 of 80) with videos related to

Pageof 8
Sort By:
JCO Precision Oncology|May 11, 2026
Detection of Homologous Recombination Repair Gene Mutations by Tumor Tissue and Circulating Tumor DNA Testing in Prostate Cancer in the Phase III PROpel TrialAndrew J Armstrong, Fred Saad, Mototsugu Oya, et al.
Cancer|July 4, 2025
Administration of nivolumab plus ipilimumab: Infusion of the fixed-ratio combination versus sequential infusions in two randomized controlled trials of metastatic melanoma (CheckMate 742) and renal cell carcinoma (CheckMate 800)Alexander M Menzies, Pamela Salman, Osvaldo Arén Frontera, et al.
BMJ Open|September 14, 2022
Multi-Arm GlioblastoMa Australasia (MAGMA): protocol for a multiarm randomised clinical trial for people affected by glioblastomaBenjamin Y Kong, Hao-Wen Sim, Elizabeth H Barnes, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|September 14, 2013
Management of advanced kidney cancer: Canadian Kidney Cancer Forum 2013 Consensus Update: Canadian Kidney Cancer Forum 2013Scott North, Naveen Basappa, Georg Bjarnason, et al.
European Urology|March 27, 2019
Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary TractCora N Sternberg, Yohann Loriot, Nicholas James, et al.
EMBO Molecular Medicine|July 13, 2010
Oncolytic targeting of renal cell carcinoma via encephalomyocarditis virusFrederik C Roos, Andrew M Roberts, Irene I L Hwang, et al.
European Journal of Cancer (Oxford, England : 1990)|May 22, 2022
Olaparib tolerability and common adverse-event management in patients with metastatic castration-resistant prostate cancer: Further analyses from the PROfound studyGuilhem Roubaud, Mustafa Özgüroğlu, Nicolas Penel, et al.
Clinical Genitourinary Cancer|June 23, 2026
Pembrolizumab and Denosumab in Clear-Cell Renal-Cell CarcinomaCarole A Harris, Danka S Zebic, Michelle F Morris, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 16, 2024
Oral Cannabis Extract for Secondary Prevention of Chemotherapy-Induced Nausea and Vomiting: Final Results of a Randomized, Placebo-Controlled, Phase II/III TrialPeter Grimison, Antony Mersiades, Adrienne Kirby, et al.
European Urology Focus|June 5, 2024
Final Results from SAUL, a Single-arm International Study of Atezolizumab in Unselected Patients with Pretreated Locally Advanced/Metastatic Urinary Tract CarcinomaCora N Sternberg, Yohann Loriot, Ernest Choy, et al.
Pageof 8

Showing results (61-70 of 80) with videos related to

Sort By:
Pageof 8
JCO Precision Oncology|May 11, 2026
Detection of Homologous Recombination Repair Gene Mutations by Tumor Tissue and Circulating Tumor DNA Testing in Prostate Cancer in the Phase III PROpel TrialAndrew J Armstrong, Fred Saad, Mototsugu Oya, et al.
Cancer|July 4, 2025
Administration of nivolumab plus ipilimumab: Infusion of the fixed-ratio combination versus sequential infusions in two randomized controlled trials of metastatic melanoma (CheckMate 742) and renal cell carcinoma (CheckMate 800)Alexander M Menzies, Pamela Salman, Osvaldo Arén Frontera, et al.
BMJ Open|September 14, 2022
Multi-Arm GlioblastoMa Australasia (MAGMA): protocol for a multiarm randomised clinical trial for people affected by glioblastomaBenjamin Y Kong, Hao-Wen Sim, Elizabeth H Barnes, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|September 14, 2013
Management of advanced kidney cancer: Canadian Kidney Cancer Forum 2013 Consensus Update: Canadian Kidney Cancer Forum 2013Scott North, Naveen Basappa, Georg Bjarnason, et al.
European Urology|March 27, 2019
Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary TractCora N Sternberg, Yohann Loriot, Nicholas James, et al.
EMBO Molecular Medicine|July 13, 2010
Oncolytic targeting of renal cell carcinoma via encephalomyocarditis virusFrederik C Roos, Andrew M Roberts, Irene I L Hwang, et al.
European Journal of Cancer (Oxford, England : 1990)|May 22, 2022
Olaparib tolerability and common adverse-event management in patients with metastatic castration-resistant prostate cancer: Further analyses from the PROfound studyGuilhem Roubaud, Mustafa Özgüroğlu, Nicolas Penel, et al.
Clinical Genitourinary Cancer|June 23, 2026
Pembrolizumab and Denosumab in Clear-Cell Renal-Cell CarcinomaCarole A Harris, Danka S Zebic, Michelle F Morris, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 16, 2024
Oral Cannabis Extract for Secondary Prevention of Chemotherapy-Induced Nausea and Vomiting: Final Results of a Randomized, Placebo-Controlled, Phase II/III TrialPeter Grimison, Antony Mersiades, Adrienne Kirby, et al.
European Urology Focus|June 5, 2024
Final Results from SAUL, a Single-arm International Study of Atezolizumab in Unselected Patients with Pretreated Locally Advanced/Metastatic Urinary Tract CarcinomaCora N Sternberg, Yohann Loriot, Ernest Choy, et al.
Pageof 8